This might be explained by the fact that PLXNB1 had increased expression in less aggressive molecular subtypes (LumA and Normal subtype) and immune infiltrate subtype (C3), while PLXNB3 and PLXND1 had increased expression in more aggressive breast cancer subtypes (Basal and Her2), immune infiltrate subtypes (C1, C2, or C6), and/or in metastatic tumors (PLXNB3). Here, PLXNB1 is linked to metastatic neoplasm.